Heinz Jakob

Heinz Jakob

Auto-generated profile, based on publicly available information

Heinz Jakob

Department of Cardiothoracic Surgery, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
HJHeinz Jakob
Heinz Jakob
KTKonstantinos Tsagakis
Konstantinos Tsagakis
PTPaschalis Tossios
Paschalis Tossios
PMParwis Massoudy
Parwis Massoudy
MTMatthias Thielmann
Matthias Thielmann
MKMarkus Kamler
Markus Kamler

1 January 2015 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
KPKevin Pilarczyk
Kevin Pilarczyk
MEMichaela Edayadiyil-Dudasova
Michaela Edayadiyil-Dudasova
Daniel WendtDaniel Wendt
Daniel Wendt
EDEnder Demircioglu
Ender Demircioglu
JBJaroslav Benedik
Jaroslav Benedik
FDFabian Dusse
Fabian Dusse
Acute kidney injury (AKI) is a common complication after cardiac surgery. Currently, prediction of AKI with classical tools remains uncertain. Therefore, it was the aim of the present study to evaluate two new urinary biomarkers—insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2) in patients after coronary artery bypass surgery (CABG). In a prospective cohort study, 60 consecutive patients undergoing isolated on-pump CABG were enrolled. Urine samples collected every 12 h in the postoperative course were analyzed for the product of TIMP-2 and IGFBP7. Urinary output, serum creatinine and estimated glomerular filtration rate (eGFR) were recorded simultaneously. Primary clinical endpoint was the development of AKI stage 2 or 3 according to the classification of the KDIGO within 48 h after surgery. 48 male and 12 female patients with a mean age of 69.61 ± 8.4 years were included. 19 patients developed an AKI (31.6 %), six patients met the endpoint with AKI 2 or 3 (10 %). Urinary [TIMP-2]*[IGFBP7] increased significantly as early as 4 h after CABG in patients with AKI 2/3 (1.83 ± 2.15 vs. 0.23 ± 0.45, p < 0.05) whereas serum creatinine did not increase until 48 h after surgery. The diagnostic accuracy of [TIMP 2]*[IGFBP7] on day one after surgery for the prediction of AKI 2/3 was significantly better (sensitivity 0.89, specificity 0.81, AUC 0.817, 95 % CI 0.622–1.0 SE 0.099, p = 0.022, cut-off 0.817) than for serum creatinine (AUC 0.359, sensitivity 0.50, specificity of 0.52, cut-off value 1.17 mg/dl) and eGFR. Urinary [TIMP-2]*[IGFBP7] represents a sensitive and specific biomarker to predict moderate to severe AKI very early after CABG. Analyses from our ongoing larger study are necessary to confirm these findings and probably increase sensitivity and specificity.

1 December 2015 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
FDFabian Dusse
Fabian Dusse
MEMichaela Edayadiyil-Dudásova
Michaela Edayadiyil-Dudásova
Matthias ThielmannMatthias Thielmann
Matthias Thielmann
Daniel WendtDaniel Wendt
Daniel Wendt
PKPhilipp Kahlert
Philipp Kahlert
KPKevin Pilarczyk
Kevin Pilarczyk
Acute kidney injury (AKI) is a common complication following transcatheter aortic valve implantation (TAVI) leading to increased mortality and morbidity. Urinary G1 cell cycle arrest proteins TIMP-2 and IGFBP7 have recently been suggested as sensitive biomarkers for early detection of AKI in critically ill patients. However, the precise role of urinary TIMP-2 and IGFBP7 in patients undergoing TAVI is unknown. In a prospective observational trial, 40 patients undergoing TAVI (either transaortic or transapical) were enrolled. Serial measurements of TIMP-2 and IGFBP7 were performed in the early post interventional course. The primary clinical endpoint was the occurrence of AKI stage 2/3 according to the KDIGO classification. Now we show, that ROC analyses of [TIMP-2]*[IGFBP7] on day one after TAVI reveals a sensitivity of 100 % and a specificity of 90 % for predicting AKI 2/3 (AUC 0.971, 95 % CI 0.914-1.0, SE 0.0299, p = 0.001, cut-off 1.03). In contrast, preoperative and postoperative serum creatinine levels as well as glomerular filtration rate (GFR) and perioperative change in GFR did not show any association with the development of AKI. Furthermore, [TIMP-2]*[IGFBP7] remained stable in patients with AKI ≤1, but its levels increased significantly as early as 24 h after TAVI in patients who developed AKI 2/3 in the further course (4.77 ± 3.21 vs. 0.48 ± 0.68, p = 0.022). Mean patients age was 81.2 ± 5.6 years, 16 patients were male (40.0 %). 35 patients underwent transapical and five patients transaortic TAVI. 15 patients (37.5 %) developed any kind of AKI; eight patients (20 %) met the primary endpoint and seven patients required renal replacement therapy (RRT) within 72 h after surgery. Early elevation of urinary cell cycle arrest biomarkers after TAVI is associated with the development of postoperative AKI. [TIMP-2]*[IGFBP7] provides an excellent diagnostic accuracy in the prediction of AKI that is superior to that of serum creatinine.

1 July 2007 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
HJHeinz Jakob
Heinz Jakob
KTKonstantinos Tsagakis
Konstantinos Tsagakis
ASAndras Szabo
Andras Szabo
IWIngo Wiese
Ingo Wiese
MTMatthias Thielmann
Matthias Thielmann
UHUlf Herold
Ulf Herold

1 May 2014 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
Daniel WendtDaniel Wendt
Daniel Wendt
Matthias ThielmannMatthias Thielmann
Matthias Thielmann
BPBjörn Plicht
Björn Plicht
JAJörg Aßmann
Jörg Aßmann
VPVivien Price
Vivien Price
HJHeinz Jakob
Heinz Jakob

9 December 2016 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
HJHeinz Jakob
Heinz Jakob
DDDaniel Dohle
Daniel Dohle
JBJaroslav Benedik
Jaroslav Benedik
RJRolf Alexander Janosi
Rolf Alexander Janosi
TSThomas Schlosser
Thomas Schlosser
KTKonstantinos Tsagakis
Konstantinos Tsagakis
OBJECTIVES: The E-vita Open hybrid stent graft is intended to achieve one-stage treatment of the proximal and distal thoracic aorta down to the mid-thoracic level in cases of acute (AAD) or chronic (CAD) type I aortic dissection and complex thoracic aortic aneurysm (TAA). We report our long-term results up to 10-year experience. METHODS: From February 2005 until March 2015, 178 consecutive patients (mean age 59 ± 11 years) underwent surgery using the E-vita Open hybrid graft for AAD (n = 96), CAD (n = 43) or TAA (n = 39). Pre-, intra- and postoperative variables, influential procedural improvements and follow-up data including aortic remodelling analyses are presented. RESULTS: Overall 30-day mortality was 10%, 10% for AAD, 7% for CAD and 13% for TAA. Univariable analysis identified low left ventricular ejection fraction, peripheral arterial disease, chronic obstructive pulmonary disease and severely compromised haemodynamics as risk factors for in-hospital death. Logistic regression analysis defined compromised haemodynamics and duration of cardiopulmonary bypass as significant. After 7 years, estimated survival was 55% for AAD, 74% for CAD and 73% for TAA patients. Freedom from aorta-related late death was 94%, 91% in AAD, 100% in CAD and 97% in TAA. Positive or stable aortic remodelling down to the stent graft end was achieved in 92% AAD, 82% in CAD and full aneurysmal exclusion in 88%. Further downstream, negative remodelling was observed in 27% of the AAD, 41% of the CAD and 22% of the TAA patients. Freedom from endovascular intervention downstream was 96% in AAD, 75% in CAD and 74% in TAA patients. Freedom from thoraco-abdominal surgery was 97%, 65% and 93%, respectively. CONCLUSIONS: The E-vita Open hybrid stent graft renders durable long-term performance without any proximal endoleakage or graft failure over time and represents the ideal landing or docking zone for either thoracic endovascular thoracic repair or thoraco-abdominal surgery, if required. No reinterventions were necessary down to the end of the stent graft, proving that the disease is overcome along the hybrid graft down to mid-thoracic level.